WESTFORD, Mass., Nov. 11, 2013 /PRNewswire/ -- Cynosure, Inc. (CYNO), which develops and markets laser- and light-based aesthetic treatment systems for high-volume applications, today announced that Chairman, Chief Executive Officer and President Michael Davin and Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy Baker will be presenting at two upcoming investor conferences.
- On Thursday, November 14 at 10:30 a.m. (ET), management will present at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York City.
- On Tuesday, November 19 at 9:05 a.m. (ET), management will participate in a fireside chat at the Barclays Select Growth Conference in New York City.
About Cynosure, Inc.
Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, treat toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 100 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com.
- Health Care Industry
- Investment & Company Information
- Chief Executive Officer